News

Technology News

Cardax Pharma Clears Equity Venture Capital

Tuesday, November 17, 2015 5:02:00 AM PDT | VentureDeal
   Honolulu, Hawaii  --  Cardax Pharmaceuticals (OTCQB: CDXI) has raised $466,000 in new equity venture capital funding, according to an SEC regulatory filing.

Cardax is "developing a platform of proprietary, exceptionally safe, small molecule compounds that impact inflammatory pathways affected by TNF-alpha, a major inflammatory cytokine."

The company is focusing its efforts on products utilizing astaxanthin, a naturally occurring inflammation reduction compound.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Cardax is still seeking $2.4 million in additional financing, according to the filing.

Minimum investment size per investor was listed as $10,000.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1